Givastomig Shows Promise in 1L Gastric Cancer: I-Mab at ESMO GI 2025
I-Mab Presents Positive Phase 1b Data for Givastomig in Combination with Nivolumab and Chemotherapy in 1L Gastric Cancer at ESMO GI 2025 I-Mab (NASDAQ: IMAB), a U.S.-based global biotechnology company…
Asahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention
Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical…
WHO Launches Drive to Boost Health Taxes, Save Lives
WHO Unveils “3 by 35” Health Tax Initiative to Combat NCDs and Boost Public Revenue The World Health Organization (WHO) has launched a bold and far-reaching global campaign aimed at…
Incyte Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
Incyte Grants Equity Awards to Incoming CEO Bill Meury Under Nasdaq Rule 5635(c)(4) Incyte Corporation (Nasdaq: INCY) announced the grant of equity inducement awards to Bill Meury, marking a key…
FDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic™ (linvoseltamab-gcpt) for Relapsed or Refractory Multiple Myeloma Regeneron Pharmaceuticals has secured a critical milestone in oncology drug development with the U.S. Food and…
FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial
FDA Grants Priority Review to Merck’s WINREVAIR™ Based on Landmark ZENITH Trial Showing Dramatic Reduction in Morbidity and Mortality in PAH Patients Merck (NYSE: MRK), operating as MSD outside the…
Gilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind
Gilead Targets HIV Prevention Dominance With Twice-Yearly Yeztugo as GSK Mounts a Defense Gilead Sciences is taking a bold step to further entrench itself as the dominant force in HIV…
Lupin Unveils New Consumer Healthcare Arm: LupinLife
Lupin Launches LupinLife as Independent Subsidiary to Strengthen Focus on India’s Self-Care Market Global pharmaceutical leader Lupin Limited has announced a significant strategic move to bolster its consumer healthcare operations.…
WHO-backed testing model boosts mpox, HIV, and syphilis response
As mpox cases surge once again in parts of Central Africa, the Democratic Republic of the Congo (DRC) is leading a bold, innovative strategy by integrating HIV and syphilis testing…
Suriname Officially Certified Malaria-Free by WHO
Suriname Becomes First Amazon Nation to Earn WHO Malaria-Free Certification In a historic public health milestone, the Republic of Suriname has been officially certified as malaria-free by the World Health…
Jazz Pharma Gets EU Nod for Ziihera in Advanced HER2+ Biliary Cancer
Jazz Pharmaceuticals Secures Conditional EU Approval for Ziihera® (zanidatamab) to Treat Advanced HER2-Positive Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that the European Commission (EC) has granted…
WuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics
WuXi Biologics Launches WuXiHigh™ 2.0 to Advance High-Concentration Biologic Formulations WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the official launch of WuXiHigh™…